BioChem Therapeutic and Oncogene Science Expand Collaboration in Antivirals.LAVAL, Quebec--(BUSINESS WIRE)--Feb. 27, 1997--ONCOGENE SCIENCE (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on :ONCS ) BIOCHEM PHARMA (ME, TSE See Tokyo Stock Exchange. TSE 1. See Tokyo Stock Exchange (TSE). 2. See Toronto Stock Exchange (TSE). :BCH., NASDAQ: BCHXF.) BioChem Therapeutic Inc. and Oncogene oncogene Gene that can cause cancer. It is a sequence of DNA that has been altered or mutated from its original form, the proto-oncogene (see mutation). Proto-oncogenes promote the specialization and division of normal cells. Science, Inc. announced today an expansion of their collaborative co-venture for the discovery and development of novel antiviral drugs. In May 1996, BioChem Therapeutic Inc. and Oncogene Science entered into a collaborative research, development and commercialization agreement for the discovery and development of antiviral drugs to treat hepatitis C (HCV HCV abbr. hepatitis C virus HCV 1 Hepatitis C virus, see there 2. Human coronavirus. See Coronavirus. ) and human immunodeficiency virus human immunodeficiency virus n. HIV. Human immunodeficiency virus (HIV) A transmissible retrovirus that causes AIDS in humans. (HIV HIV (Human Immunodeficiency Virus), either of two closely related retroviruses that invade T-helper lymphocytes and are responsible for AIDS. There are two types of HIV: HIV-1 and HIV-2. HIV-1 is responsible for the vast majority of AIDS in the United States. ). Under terms of the agreement, BioChem Therapeutic and Oncogene Science will pursue additional viral targets utilizing Oncogene Science's platform of drug discovery technologies. "BioChem Therapeutic is an emerging force in the area of antiviral drugs," stated Gary E. Frashier, Chief Executive Officer of Oncogene Science, Inc. "Oncogene Science's proprietary drug discovery technology platform together with BioChem Therapeutic's proven drug optimization capabilities is a powerful combination with which to generate a pipeline of novel, small molecule antiviral drugs." "BioChem Therapeutic is committed to the development of a broad portfolio of antiviral drugs," stated Michael G. Grey, President, BioChem Therapeutic Inc. "Oncogene Science is an integral part of our strategy in this area and we are very pleased with the progress that has been made in the program to date." Oncogene Science, Inc. is a leading pharmaceutical discovery company applying a platform of proprietary, broadly enabling technologies to drive a substantial pipeline of novel, small molecule drug candidates and transition them into clinical development. The Company conducts multiple drug discovery and development programs targeting major human diseases independently and in co-ventures and collaborations with major pharmaceutical companies. Additional information on Oncogene Science, Inc. is available on the World Wide Web at: http://www.oncogene.com . BioChem Therapeutic Inc. is a wholly owned subsidiary Wholly Owned Subsidiary A subsidiary whose parent company owns 100% of its common stock. Notes: In other words, the parent company owns the company outright and there are no minority owners. of BioChem Pharma Inc. BioChem Pharma is an international company dedicated to the research, development and commercialization of innovative products for the prevention, detection and treatment of human diseases. The company, celebrating it's tenth anniversary, lists its common shares on the Montreal and Toronto Stock Exchanges (BCH) and on the NASDAQ stock market Nasdaq stock market The first electronic stock market listing over 5000 companies. The Nasdaq stock market comprises two separate markets, namely the Nasdaq National Market, which trades large, active securities and the Nasdaq Smallcap Market that trades emerging growth companies. (BCHXF). BioChem Pharma news releases and other company information can now be found on the World Wide Web at: http://www.biochem-pharma.com . CONTACT: BioChem Therapeutic Inc. Michele Roy, 514/978-7938 corpcom@biochem-pharma.com or Oncogene Science, Inc. Matthew D. Haines, 516/222-0023 mhaines@oncogene.com |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion